Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors
January 02, 2020 at 04:15 pm EST
Share
Plus Therapeutics, Inc. announced that Dr. An van Es-Johansson has joined the Company’s Board of Directors to serve as an independent director, effective January 1, 2020. Dr. van Es-Johansson currently serves as the Chief Medical Officer for AlzeCure Pharma, where she is responsible for regulatory, clinical development, clinical operations, and pharmacovigilance. From 2005-2018, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Swedish Orphan Biovitrum AB (Sobi), an international specialty biopharmaceutical company focused on rare diseases. Dr. van Es-Johansson has leadership experience within large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech, and BioStratum. She currently serves on the Board of Directors at BioInvent International AB, Medivir AB, Agendia Inc., Savara Inc., and AlzeCure Pharma AB.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.